.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech intend to note on the Nasdaq under the icon “BIOA,” according to documentations submitted with the Securities and Substitution Percentage. The company has actually certainly not openly shared an anticipated financial volume for the offering.The clinical-stage provider touts lead prospect azelaprag, an orally provided little molecule slated to enter into stage 2 testing in combo along with semaglutide– marketed through Novo Nordisk under trademark name Wegovy for effective weight loss– in the first half of following year. Semaglutide is actually additionally sold as Ozempic as well as Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is actually designed to combine effectively with GLP-1 medicines, increasing weight management while protecting muscle mass. The investigational medicine was actually located to become well-tolerated among 265 people around eight stage 1 trials, depending on to BioAge.Recently, BioAge gathered the help of Lilly to manage a trial mixing azelaprag along with the Huge Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetic issues as Mounjaro as well as Zepbound for fat loss. The partners are presently conducting a phase 2 trial of azelaprag and also tirzepatide, with topline results assumed in the 3rd one-fourth of 2025.The biotech is additionally planning an insulin sensitiveness proof-of-concept trial examining azelaprag as a monotherapy in the first half of upcoming year to sustain potential indicator growth.
In addition, the business considers to inquire the FDA for authorization in the 2nd one-half of 2025 to introduce individual screening for an NLRP3 prevention targeting metabolic illness and neuroinflammation.BioAge’s anticipated move to the general public market complies with a slight uptick in organized biotech IPOs coming from Bicara Therapeutics and also Zenas Biopharma. Zooming out, the recent IPO garden is actually a “combined image,” along with top notch providers still debuting on the public markets, just in lowered varieties, according to PitchBook.